Granulocyte Colony Stimulating Factor for for the Prevention of Febrile Neutropenia in Epithelial Ovarian Cancer
Status:
Unknown status
Trial end date:
2020-10-01
Target enrollment:
Participant gender:
Summary
This study aims to analyze the effects of long-acting versus short-acting granulocyte colony
stimulating factor (G-CSF) on the prevention febrile neutropenia (FN) in epithelial ovarian
cancer patients.
Patients receive platinum-based chemotherapy of 3 to 4 weeks. Patients are randomized into
study group and control group. In study group, patients accept long-acting G-CSF 48 hours
from the chemotherapy. While the control group accept regular or prophylactic treatment of
short-acting G-CSF according to National Comprehensive Cancer Network guidelines.
The primary end is the incidence of FN in every course of chemotherapy.
The secondary ends include: the incidences of myelosuppression, doses of G-CSF and its
expenses, visits to outpatient and emergency clinics, adverse events related to G-CSF,
quality of life, and survival outcomes (progression-free survival and overall survival).
Phase:
Phase 3
Details
Lead Sponsor:
Lei Li
Collaborators:
Beijing Hospital China-Japan Friendship Hospital Seventh Medical Center of PLA Army General Hospital the Seventh Medical Center of PLA General Hospital The Sixth Medical Center of PLA General Hospital